<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The transformation of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) to high-grade histology occurs in up to 70% of patients </plain></SENT>
<SENT sid="1" pm="."><plain>The role of hematopoietic stem cell transplantation (HSCT) in transformed FL is poorly defined </plain></SENT>
<SENT sid="2" pm="."><plain>Twenty-four FL patients with histologically confirmed transformation to diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> underwent unpurged autologous HSCT at our institution </plain></SENT>
<SENT sid="3" pm="."><plain>Their median age was 56 yr </plain></SENT>
<SENT sid="4" pm="."><plain>The median number of prior chemotherapies was 2 (range 1-6) </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen patients had residual nodal disease measuring more than 2 cm and four patients had bulky disease at the time of HSCT </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients had refractory disease at transplantation </plain></SENT>
<SENT sid="7" pm="."><plain>At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40% </plain></SENT>
<SENT sid="8" pm="."><plain>The 3-yr overall survival was 52% </plain></SENT>
<SENT sid="9" pm="."><plain>The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively </plain></SENT>
</text></document>